COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK

被引：0
|
作者：
Schlueter, M. [1 ]
Vega-Hernandez, G. [2 ]
Wojcik, R. [1 ]
机构：
[1] IMS Hlth, London, England
[2] Novo Nordisk Ltd, Gatwick, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1886
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A675 / A675
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [2] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    Diabetes Therapy, 2017, 8 : 513 - 530
  • [3] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [4] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [5] THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
    Lin, H.
    Babineaux, S.
    Lew, T.
    Lowin, J.
    Lovato, E.
    Strizek, A. A.
    Rajan, N.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Manrique, H.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
  • [7] DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [8] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [9] Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran
    Ekhlasi, Mahna
    Taheri, Saeed
    Yousefi, Nazila
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 54 - 61
  • [10] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA
    Shao, H.
    Shi, L.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
12345